<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916886</url>
  </required_header>
  <id_info>
    <org_study_id>JSVCT118</org_study_id>
    <nct_id>NCT04916886</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.</brief_title>
  <official_title>To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CanSino Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CanSino Biologics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single-center, randomized and double-blinded trial to evaluate the&#xD;
      immunobridging between different manufacture scales, lot-to-lot consistency of the&#xD;
      Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)(Ad5-nCOV) in population 6-59&#xD;
      years of age. The immunobridging between different manufacture scales will be evaluated&#xD;
      first, the immunobridging between different age groups will be evaluated second, the&#xD;
      lot-to-lot consistency will be evaluated at last.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMT of anti SARS-CoV-2 specific neutralizing antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>GMT of anti SARS-CoV-2 specific neutralizing antibody in all groups (wild type variants test).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate of SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>Seroconversion rate of anti SARS-CoV-2 specific neutralizing antibody (wild type variants test).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMI of SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>GMI of anti SARS-CoV-2 specific neutralizing antibody (wild type variants test).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of SARS-CoV-2 S protein RBD antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>GMT of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate of SARS-CoV-2 S protein RBD antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>Seroconversion rate of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMI of SARS-CoV-2 S protein RBD antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>GMI of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Ad5 vector neutralizing antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>GMT of anti Ad5 vector neutralizing antibody responses post vaccination in all groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMI of Ad5 vector neutralizing antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>GMI of Ad5 vector neutralizing antibody responses post vaccination in all groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stratified analysis on Ad5 vector neutralizing antibody</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>Stratified analysis based on the GMT of Ad5 vector neutralizing antibody responses post vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Reactions/Events (AE/AR)</measure>
    <time_frame>Within 30 minutes after vaccination</time_frame>
    <description>The occurance of Adverse Reactions/Events within 30 minutes post vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Reactions/Events (AE/AR)</measure>
    <time_frame>Within 0-7 days after vaccination</time_frame>
    <description>The occurance of Adverse Reactions/Events (AE/AR) within 7 days post vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Reactions/Events (AE/AR)</measure>
    <time_frame>Within 0-28 days after vaccination</time_frame>
    <description>The occurance of Adverse Reactions/Events (AE/AR) within 28 days post vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>Within 12 months after vaccination</time_frame>
    <description>Occurance of Serious Adverse Events (SAE) post vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Within 12 months after vaccination</time_frame>
    <description>Occurance of Adverse Events of Special Interest (AESI) post vaccination.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">2016</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>50L Scale (Age 18-59)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500L Scale (Age 18-59)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800L Scale (Age 18-59)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800L Scale Lot 1 (Age 13-17)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800L Scale Lot 2 (Age 13-17)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800L Scale Lot 3 (Age 13-17)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800L Scale Lot 1 (Age 6-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800L Scale Lot 2 (Age 6-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800L Scale Lot 3 (Age 6-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml</intervention_name>
    <description>Containing 0.5E10vp</description>
    <arm_group_label>500L Scale (Age 18-59)</arm_group_label>
    <arm_group_label>50L Scale (Age 18-59)</arm_group_label>
    <arm_group_label>800L Scale (Age 18-59)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml</intervention_name>
    <description>Containing 0.3E10vp</description>
    <arm_group_label>800L Scale Lot 1 (Age 13-17)</arm_group_label>
    <arm_group_label>800L Scale Lot 1 (Age 6-12)</arm_group_label>
    <arm_group_label>800L Scale Lot 2 (Age 13-17)</arm_group_label>
    <arm_group_label>800L Scale Lot 2 (Age 6-12)</arm_group_label>
    <arm_group_label>800L Scale Lot 3 (Age 13-17)</arm_group_label>
    <arm_group_label>800L Scale Lot 3 (Age 6-12)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  6-59 years of age at the time of enrollment;&#xD;
&#xD;
          -  Able to provide consent or obtain consent from guardian to participate in the trial&#xD;
             and sign an Informed Consent Form (ICF);&#xD;
&#xD;
          -  Able and willing to complete all the scheduled study procedures during the whole study&#xD;
             follow-up period;&#xD;
&#xD;
          -  Axillary temperature ≤37.0℃;&#xD;
&#xD;
          -  IgG ang IgM negative for Covid-19;&#xD;
&#xD;
          -  Have not received any type of Covid-19 vaccines;&#xD;
&#xD;
          -  No contact history of Covid-19; no travel history to medium and high risk regions and&#xD;
             abroad in the past 21 days;&#xD;
&#xD;
          -  Participants who are clinically determined to be healthy after checking medical&#xD;
             history and physical examination are eligible to receive the product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical or family history of convulsions, epilepsy, encephalopathy, and psychosis&#xD;
             disorders;&#xD;
&#xD;
          -  History of allergies to any ingredient of Ad5-nCoV, history of serious allergic&#xD;
             reactions to any vaccine, history of allergies and immune diseases;&#xD;
&#xD;
          -  Women who are pregnant or lactating, positive urine pregnancy test or plan to become&#xD;
             pregnant during the 12 months study period;&#xD;
&#xD;
          -  Acute febrile diseases and infectious diseases, medical history of SARS (SARS-CoV-1);&#xD;
&#xD;
          -  Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial&#xD;
             infarction, severe hypertension and uncontrollable medications (on-site measurement&#xD;
             for 18-59 years of age: systolic blood pressure ≥160mmHg, diastolic blood pressure&#xD;
             ≥100mmHg), etc;&#xD;
&#xD;
          -  Severe chronic diseases or with advanced stage conditions which cannot be controlled&#xD;
             smoothly, such as diabetes, thyroid disease, etc;&#xD;
&#xD;
          -  Congenital or acquired angioedema/neurological edema;&#xD;
&#xD;
          -  Urticaria history within 1 year before receiving the study vaccine;&#xD;
&#xD;
          -  Asplenia or functional aspleenia;&#xD;
&#xD;
          -  Thrombocytopenia or other coagulation disorders (may cause contraindications for&#xD;
             intramuscular injection);&#xD;
&#xD;
          -  Trypanophobia；&#xD;
&#xD;
          -  History of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic&#xD;
             therapy, nebulized corticosteroid therapy in the past 6 months (not including&#xD;
             corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid&#xD;
             treatment for acute non-complicated dermatitis);&#xD;
&#xD;
          -  Prior administration of blood products in last 4 months;&#xD;
&#xD;
          -  Received other investigational drugs within 1 month before the study;&#xD;
&#xD;
          -  Prior administration of live attenuated vaccines within 1 month before the study;&#xD;
&#xD;
          -  Prior administration of subunit or inactivated vaccines within 14 days before the&#xD;
             study;&#xD;
&#xD;
          -  Current anti-tuberculosis therapy;&#xD;
&#xD;
          -  Medical history of Covid-19 disease/infection;&#xD;
&#xD;
          -  Any condition that in the opinion of the investigators may interfere with the&#xD;
             participants' compliance or evaluation of study objectives or informed consent (i.e.&#xD;
             medical, psychological, social or other conditions, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengcai Zhu, MSD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincal Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fengcai Zhu, MSD</last_name>
    <phone>+8613951994867</phone>
    <email>jszfc@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Funing Center for Disease Control and Prevention</name>
      <address>
        <city>Yancheng</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengcai Zhu, MSD</last_name>
      <phone>+8613951994867</phone>
      <email>jszfc@vip.sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Ad5</keyword>
  <keyword>Immunobridging</keyword>
  <keyword>Lot-to-lot consistency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

